Glaucoma risk factor assessment and prevention: Lessons from coronary heart disease

American Journal of Ophthalmology

Volumn 138, Issue 3 SUPPL., 2004, Pages 11-18

  Girkin, Christopher A ^a,e   Kannel, William B ^b   Friedman, David S ^c   Weinreb, Robert N ^d  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE DISTRIBUTION; CARDIOVASCULAR RISK; DISEASE COURSE; GLAUCOMA; HUMAN; INCIDENCE; INTRAOCULAR HYPERTENSION; ISCHEMIC HEART DISEASE; LIFE EXPECTANCY; MEDICAL PRACTICE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK FACTOR; TREATMENT PLANNING; VISUAL DISORDER;

EID: 4444362885     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2004.04.060     Document Type: Article

References (48)

1. Gordon M.O., Kass M.A. Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study. Design and baseline description of the participants. Arch Ophthalmol. 117:1999;573-583
2. Gordon M.O., Beiser J.A., Brandt J.D., et al. Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study. Baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 120:2002;714-720
3. Kass M.A., Heuer D.K., Higginbotham E.J., et al. Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study. A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 120:2002;701-713
4. Kannel W.B. Contributions of the Framingham Study to the conquest of coronary artery disease [editorial]. Am J Cardiol. 62:1988;1109-1112
5. National Cholesterol Education Program (NCEP) Expert Panel. Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final Report. National Institutes of Health Publication No. 02-5215. Washington, DC: National Heart, Lung and Blood Institute, National Institutes of Health, 2002
6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497
7. Grundy S.M., Balady G.J., Criqui M.H., et al. Primary prevention of coronary heart disease guidance from Framingham. A statement for healthcare professionals from the AHA Task Force on Risk Reduction. Circulation. 97:1998;1876-1887
8. Stamler J., Wentworth D., Neaton J.D. MRFIT Research Group. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 256:1986;2823-2828
9. Kannel W.B., Neaton J.D., Wentworth D., et al. MRFIT Research Group. Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT. Am Heart J. 112:1986;825-836
10. Cullen P., Funke H., Schulte H., Assmann G. Lipoproteins and cardiovascular risk - from genetics to CHD prevention. Eur Heart J. 19:(C Suppl):1998;C5-C11
11. LaRosa J.C., He J., Vupputuri S. Effect of statins on risk of coronary disease. A meta-analysis of randomized controlled trials. JAMA. 282:1999;2340-2346
12. Kannel W.B., Wilson P.W.F. Efficacy of lipid profiles in prediction of coronary disease. Am Heart J. 124:1992;768-774
13. Kannel W.B. Prospects for prevention of cardiovascular disease in the elderly. Prev Cardiol. 1:1998;32-39
14. Stampfer M.J., Sacks F.M., Salvini S., Willett W.C., Hennekens C.H. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med. 325:1991;373-381
15. Pearson T.A. New tools for coronary risk assessment. What are their advantages and limitations? Circulation. 105:2002;886-892
16. Kannel W.B. Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol. 76:(C Suppl):1995;69C-77C
17. Grundy S.M., Pasternak R., Greenland P., Smith S. Jr, Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol. 34:1999;1348-1359
18. Criqui M.H., Cowan L.D., Heiss G., Haskell W.L., Laskarzewski P.M., Chambless L.E. Frequency and clustering of nonlipid coronary risk factors in dyslipoproteinemia. The Lipid Research Clinics Program Prevalence Study. Circulation. 73:(1 Suppl):1986;I-40-I-50
19. Zavaroni I., Dall'Aglio E., Bonora E., Alpi O., Passeri M., Reaven G.M. Evidence that multiple risk factors for coronary artery disease exist in persons with abnormal glucose tolerance. Am J Med. 83:1987;609-612
20. Genest J. Jr, Cohn J.S. Clustering of cardiovascular risk factors targeting high-risk individuals. Am J Cardiol. 76:(A Suppl):1995;8A-20A
21. Kannel W.B., Wilson P.W.F. Hypertension, macrovascular disease and diabetes mellitus. William B. Hypertension in diabetes. 2003;29 Martin Dunitz, London
22. Schmidt M.I., Watson R.L., Duncan B.B., et al. Atherosclerosis Risk in Communities Study Investigators. Clustering of dyslipidemia, hyperuricemia, diabetes and hypertension and its association with fasting insulin and central and overall obesity in a general population. Metabolism. 45:1996;699-706
23. Grundy S.M. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation. 95:1997;1-4
24. Aznar J., Estelles A., Tormo G., et al. Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. Br Heart J. 59:1988;535-541
25. Zitoun D., Bara L., Basdevant A., Samama M.M. Levels of factor VIIc associated with decreased tissue factor pathway inhibitor and increased plasminogen activator inhibitor-1 in dyslipidemias. Arterioscler Thromb Vasc Biol. 1:1996;77-81
26. Scarabin P.-Y., Aillaud M.-F., Amouyel P., et al. Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction. The PRIME Study. Thromb Haemost. 80:1998;749-756
27. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 342:2000;836-843
28. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 336:1997;973-979
29. Kervinen H., Palosuo T., Manninen V., Tenkanen L., Vaarala O., Mänttäri M. Joint effects of C-reactive protein and other risk factors on acute coronary events. Am Heart J. 141:2001;580-585
30. Blackburn R., Giral P., Bruckert E., et al. Elevated C-reactive protein constitutes an independent predictor of advanced carotid plaques in dyslipidemic subjects. Arterioscler Thromb Vasc Biol. 21:2001;1962-1968
31. Kannel W.B. Risk stratification in hypertension new insights from the Framingham Study. Am J Hypertens. 13:(1 Suppl):2000;3S-10S
32. Grundy S.M. United States Cholesterol Guidelines 2001 expanded scope of intensive low-density lipoprotein-lowering therapy. Am J Cardiol. 88:(J Suppl):2001;23J-27J
33. Pearson T.A., Laurora I., Chu H., Kafonek S. The Lipid Treatment Assessment Project (L-TAP). A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 160:2000;459-467
34. Graham P.A. Epidemiology of simple glaucoma and ocular hypertension. Br J Ophthalmol. 56:1972;223-229
35. Sommer A., Tielsch J.M., Katz J., et al. Baltimore Eye Survey Research Group. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. Arch Ophthalmol. 109:1991;1090-1095
36. Leske M.C., Wu S.-Y., Nemesure B., Hennis A. Barbados Eye Studies Group. Incident open-angle glaucoma and blood pressure. Arch Ophthalmol. 120:2002;954-959
37. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS) 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 130:2000;429-440
38. Criqui M.H., Golomb B.A. Epidemiologic aspects of lipid abnormalities. Am J Med. 105:(Suppl):1998;48S-57S
39. Medeiros F.A., Sample P.A., Weinreb R.N. Corneal thickness measurements and frequency doubling technology perimetry abnormalities in ocular hypertensive eyes. Ophthalmology. 110:2003;1903-1908
40. Medeiros F.A., Sample P.A., Weinreb R.N. Corneal thickness measurements and visual function abnormalities in ocular hypertensive patients. Am J Ophthalmol. 135:2003;131-137
41. Medeiros F.A., Sample P.A., Zangwill L.M., Bowd C., Aihara M., Weinreb R.N. Corneal thickness as a risk factor for visual field loss in patients with preperimetric glaucomatous optic neuropathy. Am J Ophthalmol. 136:2003;805-813
42. Brandt J.D., Beiser J.A., Kass M.A., Gordon M.O. Ocular Hypertension Treatment Study (OHTS) Group. Central corneal thickness in the Ocular Hypertension Treatment Study (OHTS). Ophthalmology. 108:2001;1779-1788
43. Herman D.C., Hodge D.O., Bourne W.M. Increased corneal thickness in patients with ocular hypertension. Arch Ophthalmol. 119:2001;334-336
44. Liu J.H.K., Kripke D.F., Hoffman R.E., et al. Nocturnal elevation of intraocular pressure in young adults. Invest Ophthalmol Vis Sci. 39:1998;2707-2712
45. Bergeå B., Bodin L., Svedbergh B. Impact of intraocular pressure regulation on visual fields in open-angle glaucoma. Ophthalmology. 106:1999;997-1005
46. Second Joint Task Force of European and Other Societies. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention. Eur Heart J. 19:1998;1434-1503
47. Hattenhauer M.G., Johnson D.H., Ing H.H., et al. The probability of blindness from open-angle glaucoma. Ophthalmology. 105:1998;2099-2104
48. Quigley H.A., Tielsch J.M., Katz J., Sommer A. Rate of progression in open-angle glaucoma estimated from cross-sectional prevalence of visual field damage. Am J Ophthalmol. 122:1996;355-363